Created On: 2020-07-15
Record Count: 10
- Bacterial Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 263902
The name of the product is SalofalkÂ® 500 mg, Granu-StixÂ®. Salofalk Granu-Stix delivers the therapeutically active antiinflammatory agent mesalamine (5-aminosalicylic acid or 5-ASA) to the distal ileum and colon by means of dual-release granules.
The patents include Pellet formulation for the treatment of the intestinal tract, and, Pellet-type formulation intended for treating the intestinal tract.
Ulcerative colitis (UC) is a disease that affects your large intestine, or colon. It causes irritation and swelling called inflammation. … UC is a type of inflammatory bowel disease, but it's different from other diseases with similar symptoms, like Crohn's disease or irritable bowel syndrome.
IPSCIO Record ID: 264191
ExtraCellular Matrix Hydrogel (ECMH), is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis.
Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon and rectum. The primary symptoms of active disease are abdominal pain and diarrhea mixed with blood. Weight loss, fever, and anemia may also occur.
IPSCIO Record ID: 266736
Licensor grants to the extent of the Licensed Territory a nonexclusive license to use the Licensed Technology as necessary to exploit all rights granted with respect to the patent rights in the Licensed Field, with the right to sublicense.
Rifaximin means rifaximin, any pharmaceutical equivalents, salts and derivatives thereof.
Rifaximin is an antibiotic used to treat traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy.
IPSCIO Record ID: 256198
– Develop, use, Commercialize, sell, offer for sale and import Product in the Licensee Territory, and,
– subject, as between Licensee and the Third Party, to the terms of the Third Party/Licensee Agreements, have Product made by Third Party, make and have made Product.
For the Cross-Licenses, Pre-Clinical Data and Clinical Data Sharing, Licensor grants:
– an exclusive right and license, including the right to grant sublicenses, to and under Pre-Clinical Data and Clinical Data that is or becomes during the term of this Agreement owned or Controlled by Licensor to develop, use, import, sell, offer for sale, and Commercialize Product in the Field in the Licensee Territory, and subject, as between Licensee and the Third Party, to the terms of the Third Party/Licensee Agreements, have Product made by the Third Party, make and have made Product; and
– consents to Licensees right of reference and use of such Pre-Clinical Data and Clinical Data in connection with Regulatory Filings in the Licensee Territory.
Trichuris suis ova shall mean the ova or eggs of the Trichuris suis worm.
The U.S. Patent Application Nos. 12/594,074 and 12/993,517 are related to the Product.
Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of your digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition.
Ulcerative colitis is a chronic disease of the large intestine, also known as the colon, in which the lining of the colon becomes inflamed and develops tiny open sores, or ulcers, that produce pus and mucous.
IPSCIO Record ID: 233469
Balsalazide means 5-[4(2-Carboxyethelcarbamoyl)-phenylazo] – salicylic acid disodium salt dihydrate.
Products means products incorporating Balsalazide, whether or not such products are covered by the Patent Rights, or any other material whose manufacture, use or sale by an unlicensed third party would constitute an infringement of any Valid Claim included within the Patent Rights.
First marketed product, Colazal, was the first new molecular entity approved in 10 years by the FDA for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the FDA for this indication in seven years. Ulcerative colitis is a chronic form of inflammatory bowel disease characterized by inflammation of the lining of the colon. Symptoms of active ulcerative colitis include rectal bleeding, abdominal pain, increased stool frequency, loss of appetite, fever and weight loss.
IPSCIO Record ID: 7344
RMS: RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).
RPC1063 for the treatment of UC: IBD is comprised of two chronic, autoimmune, GI inflammatory disorders: UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.
IPSCIO Record ID: 239024
Licensor possesses significant expertise in the field of antiinflammatory therapeutics, and dersalazine represents the culmination of years of internal research.
Dersalazine is a new chemical entity that combines a well-known anti-inflammatory agent, 5-ASA, with a novel potent agent that acts as a PAF antagonist and an inhibitor of key interleukin cytokines to achieve a synergistic therapeutic effect when compared to the activities of each component separately. Chemical cleavage of dersalazine by colonic bacteria releases the two active compounds for the topical treatment of inflammation in the colon. The 5-ASA molecule contained in dersalazine has known antioxidant properties which may ameliorate the deleterious inflammatory effects ascribed to the overproduction of free radicals.
IPSCIO Record ID: 30510
IPSCIO Record ID: 210693
IPSCIO Record ID: 57817
Gastroenteritis, also known as infectious diarrhea, is inflammation of the gastrointestinal tractâ€”the stomach and small intestine.
Gastritis is inflammation of the lining of the stomach.
Gastroenteritis and gastritis – 24 mg strength
Irritable Bowel Syndrome with Diarrhea (IBS-D) – 12 mg strength
Prevention of chemotherapy and radiotherapy induced nausea and vomiting (oncology support) â€“ 24 mg strength